...
首页> 外文期刊>Indian journal of pharmacology. >Oral doxycycline with topical tacrolimus for treatment of stasis dermatitis due to chronic venous insufficiency: A pilot study
【24h】

Oral doxycycline with topical tacrolimus for treatment of stasis dermatitis due to chronic venous insufficiency: A pilot study

机译:口服多西环素联合他克莫司治疗慢性静脉功能不全引起的淤滞性皮炎

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Chronic venous insufficiency (CVI) in lower limbs manifest as stasis dermatitis. The anti-collagenase, anti-inflammatory and immunomodulatory effects of doxycycline and the T-cell inhibitory effects of tacrolimus could theoretically modify the disease pathophysiology. This study was undertaken to evaluate the efficacy and safety of four weeks combination therapy of oral doxycycline 100 mg with topical tacrolimus 0.1% for stasis dermatitis associated with CVI. Materials and Methods: A single-arm, interventional pilot study was conducted on subjects with CVI of C4 to C6 category (CEAP classification: clinical, etiology, anatomical, pathophysiology). Treatment duration was four weeks with fortnightly follow-ups. Primary efficacy was assessed as changes from baseline of pigmentation, erythema, edema, itching and hair loss of the affected area evaluated on Likert scale scores. Secondary efficacy parameters were percentage improvement of the dermatitis area and changes in ulcer dimensions (maximum length and breadth), if present. Safety evaluation included all treatment emergent clinical signs and symptoms reported by the patients and/or observed by the physician. Results: Out of 19 recruited subjects, 15 completed the study for analysis. Significant (P<0.01) improvement in pain, edema, pigmentation, erythema and exudation were observed. Reduction of ulcer dimensions was also statistically significant (P<0.01). 86.6% showed improvement of the dermatitis area, 6.7% patients failed to show any improvement and 6.7% showed worsening. Adverse effects were observed in only two subjects. Conclusion: This pilot study suggests efficacy of this combination therapy in controlling features of stasis dermatitis but further studies are needed for validation.
机译:目的:下肢慢性静脉功能不全(CVI)表现为瘀滞性皮炎。从理论上说,强力霉素的抗胶原酶,抗炎和免疫调节作用以及他克莫司对T细胞的抑制作用可以从理论上改变疾病的病理生理。进行这项研究以评估口服强力霉素100 mg与局部他克莫司0.1%口服治疗4周合并CVI的皮炎的疗效和安全性。材料和方法:对C4为C6到C6类别(CEAP分类:临床,病因,解剖学,病理生理学)的受试者进行了单臂介入试验研究。治疗时间为四个星期,每两周进行一次随访。主要疗效被评估为根据李克特量表评分对患处的色素沉着,红斑,水肿,瘙痒和脱发的基线变化。次要疗效参数是皮炎面积改善的百分比和溃疡尺寸(最大长度和宽度)的变化(如果存在)。安全性评估包括由患者报告和/或医师观察到的所有治疗中出现的临床症状和体征。结果:在19名招募受试者中,有15名完成了研究以进行分析。观察到疼痛,浮肿,色素沉着,红斑和渗出明显改善(P <0.01)。溃疡尺寸的减少也具有统计学意义(P <0.01)。 86.6%的患者表现出皮炎区域的改善,6.7%的患者没有表现出任何改善,而6.7%的患者表现出恶化。仅在两个受试者中观察到不良反应。结论:该初步研究表明该联合疗法在控制瘀滞性皮炎特征方面的功效,但尚需进一步研究以进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号